- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04513912
항우울제 치료에 부적절하게 반응한 불면증 증상을 동반한 주요 우울 장애가 있는 성인 및 노인 대상자의 항우울제 보조 요법으로서 셀토렉산트와 퀘티아핀 XR을 비교한 연구
항우울제 요법에 부적절하게 반응한 불면증 증상을 동반한 주요 우울 장애가 있는 성인 및 노인 환자를 대상으로 항우울제의 보조 요법으로 셀토렉산트 20mg의 효능 및 안전성을 평가하기 위한 대조약으로 퀘티아핀 서방형을 사용한 이중맹검, 무작위, 병렬 그룹 연구
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
연구 개요
상태
정황
상세 설명
Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Jelgava, 라트비아, LV-3008
- The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
-
Liepāja, 라트비아, LV-3401
- L. Keruze Practice in Psychiatry
-
Outpatient Centre of Psychiatry, 라트비아, LV-4601
- Hospital of Rezekne
-
Riga, 라트비아, LV-1002
- Riga Centre of Psychiatry and Narcology
-
-
-
-
-
Engel's, 러시아 제국, 413124
- Engels psychiatric hospital
-
Kemerovo, 러시아 제국, 650036
- Kemerovo Regional Clinical Psychiatric Hospital
-
Lipetsk Region, 러시아 제국, 399313
- GUZ Lipetsk Regional psychoneurological Hospital #1
-
Moscow, 러시아 제국, 105082
- JSC Scientific Centre of Personalized Medicine
-
Moscow, 러시아 제국, 107076
- FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
-
Moscow, 러시아 제국, 107076
- Moscow Scientific Research Institute of Psychiatry
-
Omsk, 러시아 제국, 644070
- Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
-
Saint Petersburg, 러시아 제국, 192019
- St-Petersburg Bekhterev Psychoneurological Research Institute
-
Tomsk, 러시아 제국, 634009
- Klinika StoLet Ltd
-
Yekaterinburg, 러시아 제국, 620030
- Sverdlov Regional Psychiatric Clinical Hospital
-
-
-
-
-
Kaunas, 리투아니아, 48259
- Kaunas Silainiu Outpatient Clinic, Public Institution
-
Kaunas, 리투아니아, 53136
- Republic Kaunas Hospital
-
Kaunas, 리투아니아, LT-44279
- Romuvos Klinika, JSC
-
Kaunas, 리투아니아, LT-50009
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics
-
Vilnius, 리투아니아, 09112
- Zirmunai Mental Health Center, Public Institution
-
Vilnius, 리투아니아, 10309
- Vilnius Mental Health Center
-
Vilnius, 리투아니아, 10204
- Antakalnis Psychiatric Consultation Centre, Public Institution
-
Šilutė, 리투아니아, 99176
- Medical Center Puriena JSC
-
-
-
-
-
Ipoh, 말레이시아, 30990
- Hospital Raja Permaisuri Bainun
-
Johor Bahru, 말레이시아, 81200
- Hospital Permai
-
Pulau Pinang, 말레이시아, 10990
- Hospital Pulau Pinang
-
Seremban, 말레이시아, 70300
- Hospital Tuanku Jaafar
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- University of Alabama at Birmingham
-
-
Arizona
-
Tucson, Arizona, 미국, 85712
- SW Biomedical Research LLC
-
-
California
-
Culver City, California, 미국, 90230
- Proscience Research Group
-
Encino, California, 미국, 91316
- Pharmacology Research Institute
-
Garden Grove, California, 미국, 92845
- Collaborative NeuroScience Network
-
Long Beach, California, 미국, 90806
- Collaborative NeuroScience Network
-
Los Alamitos, California, 미국, 90720
- Pharmacology Research Institute
-
Los Angeles, California, 미국, 90025
- CalNeuro Research
-
Newport Beach, California, 미국, 92660
- Pharmacology Research Institute
-
Orange, California, 미국, 92868
- NRC Research Institute
-
Orange, California, 미국, 92868
- Pacific Neuropsychiatric Specialists
-
Pico Rivera, California, 미국, 90660
- CNRI-Los Angeles, LLC
-
Rancho Cucamonga, California, 미국, 91730
- Prospective Research Innovations Inc
-
Redlands, California, 미국, 92374
- Anderson Clinical Research
-
San Diego, California, 미국, 92103
- University of California at San Diego
-
Santa Ana, California, 미국, 92705
- CI Trials
-
Santa Ana, California, 미국, 91704
- National Research Institute
-
Santee, California, 미국, 92071
- CMB Clinical Trials
-
Sherman Oaks, California, 미국, 91403
- Schuster Medical Research Institute
-
Upland, California, 미국, 91786
- Pacific Clinical Research Medical Group
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06102
- Hartford Hospital
-
-
Florida
-
Doral, Florida, 미국, 33166
- Moonshine Research Center, Inc
-
Hallandale, Florida, 미국, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, 미국, 33012
- Indago Research & Health Center Inc
-
Hialeah, Florida, 미국, 33012
- New Life Medical Research Center, Inc.
-
Hialeah, Florida, 미국, 33013
- Amedica Research Institute Inc
-
Lakeland, Florida, 미국, 33803
- Meridien Research
-
Miami, Florida, 미국, 33122
- Premier Clinical Research
-
Miami, Florida, 미국, 33125
- Global Medical Institutes
-
Miami, Florida, 미국, 33137
- Miami Jewish Health System
-
Orlando, Florida, 미국, 32806
- Synexus Research Orlando
-
Orlando, Florida, 미국, 23801
- Clinical Neuroscience Solutions
-
Tampa, Florida, 미국, 33612
- University of South Florida
-
The Villages, Florida, 미국, 32162
- Compass Research LLC-Bioclinica Research
-
-
Georgia
-
Atlanta, Georgia, 미국, 30331
- Atlanta Center for Medical Research
-
Atlanta, Georgia, 미국, 30328
- Synexus Clinical Research US Inc
-
Decatur, Georgia, 미국, 30030
- iResearch Atlanta LLC
-
Marietta, Georgia, 미국, 30060
- Psych Atlanta, P.C.
-
-
Illinois
-
Chicago, Illinois, 미국, 60634
- Chicago Research Center
-
Libertyville, Illinois, 미국, 60048
- Capstone Clinical Research
-
Lisle, Illinois, 미국, 60532
- Alexian Brothers Health System
-
Naperville, Illinois, 미국, 60563
- Baber Research Group
-
Oakbrook Terrace, Illinois, 미국, 60618
- Lemah Creek Clinical Research
-
-
Kansas
-
Wichita, Kansas, 미국, 67214
- Ascension via Christi Research
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70115
- Riverstar Research
-
-
Maryland
-
Baltimore, Maryland, 미국, 21208
- Pharmasite Research, Inc.
-
-
Massachusetts
-
New Bedford, Massachusetts, 미국, 02740
- BTC of New Bedford
-
Roslindale, Massachusetts, 미국, 02135
- Boston Clinical Trials & Medical Research
-
-
Missouri
-
O'Fallon, Missouri, 미국, 63368
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, 미국, 08755
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, 미국, 11235
- SPRI Clinical Trials, LLC
-
New York, New York, 미국, 10128
- The Medical Research Network, LLC
-
New York, New York, 미국, 10017
- Fieve Clinical Research Inc
-
Rochester, New York, 미국, 14618 1609
- Finger Lakes Clinical Research
-
Staten Island, New York, 미국, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Durham, North Carolina, 미국, 27701
- Velocity Clinical Research, Inc.
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
-
Dayton, Ohio, 미국, 45417
- Midwest Clinical Research Center
-
North Canton, Ohio, 미국, 44720
- Neuro Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112
- Sooner Clinical Research
-
Oklahoma City, Oklahoma, 미국, 73118
- Paradigm Research Professionals, LLC
-
-
Pennsylvania
-
Pine Hill, Pennsylvania, 미국, 08021
- Suburban Research Associates
-
Scranton, Pennsylvania, 미국, 18503
- Global Medical Institutes
-
-
South Carolina
-
Mt. Pleasant, South Carolina, 미국, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Bellaire, Texas, 미국, 77401
- West Houston Clinical Research Service
-
Fort Worth, Texas, 미국, 76104
- North Texas Clinical Trials
-
Mansfield, Texas, 미국, 76054
- Hawkins Psychiatry, PC
-
The Woodlands, Texas, 미국, 77381
- Family Psychiatry of The Woodlands
-
Wichita Falls, Texas, 미국, 76309
- Grayline Research Center
-
-
Utah
-
Clinton, Utah, 미국, 84015
- Alpine Research Organization
-
Draper, Utah, 미국, 84020
- Cedar Clinical Research
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- University of Virginia
-
-
Washington
-
Bellevue, Washington, 미국, 98007
- Northwest Clinical Research Center
-
Everett, Washington, 미국, 98201
- Core Clinical Research
-
-
Wisconsin
-
Waukesha, Wisconsin, 미국, 53188
- Cary J. Kohlenberg, MD, SC, dba, IPC Research.
-
-
-
-
-
Bruges, 벨기에, 8310
- AZ Sint-Lucas
-
Sint-Niklaas, 벨기에, 9100
- AZ Nikolaas
-
-
-
-
-
Pleven, 불가리아, 5800
- Medical Center Medconsult-Pleven
-
Plovdiv, 불가리아, 4028
- MC 'Hipokrat - N', EOOD
-
Rousse, 불가리아, 7003
- Mental Health Center - Rousse
-
Sofia, 불가리아, 1680
- Medical Center Intermedica, OOD
-
Sofia, 불가리아, 1113
- Medical Center St. Naum
-
Sofia, 불가리아, 1784
- MC 'Synexus Sofia' EOOD
-
Stara Zagora, 불가리아, 6003
- UMHAT Prof. Dr. St. Kirkovich AD
-
Stara Zagora, 불가리아, 6000
- MC 'Synexus Sofia' EOOD
-
Tzarev Brod, 불가리아, 9747
- State Psychiatric Hospital - Tzarev Brod
-
Varna, 불가리아, 9020
- Diagnostic Consulting Center Mladost - M Varna
-
Veliko Tarnovo, 불가리아, 5000
- Mental Health Center - Veliko Tarnovo EOOD
-
-
-
-
-
Belgrade, 세르비아, 11000
- University Clinical Center of Serbia
-
Belgrade, 세르비아, 11000
- General Hospital Euromedik
-
Belgrade, 세르비아, 11000
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Belgrade, 세르비아, 11000
- General Hospital Acibadem Bel Medic
-
Belgrade, 세르비아, 11000
- Institute of Mental Health Serbia
-
Kovin, 세르비아, 26220
- Special Neuropsychiatric Hospital Kovin
-
Kragujevac, 세르비아, 34000
- University Clinical Center Kragujevac
-
Niš, 세르비아, 18000
- Clinical Center Nis
-
Novi Kneževac, 세르비아, 23330
- Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
-
-
-
-
-
Banská Bystrica, 슬로바키아, 97401
- Psychomed-Svatosavsky, s.r.o.
-
Bojnice, 슬로바키아, 97201
- Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
-
Košice, 슬로바키아, 040 11
- Epamed sro
-
Liptovský Mikuláš, 슬로바키아, 03123
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, 슬로바키아, 97901
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Trenčín, 슬로바키아, 91101
- FN Trencin
-
Trenčín, 슬로바키아, 91108
- Pro mente sana s.r.o.
-
Žilina, 슬로바키아, 1207
- Fakultna nemocnica s poliklinikou v Ziline
-
-
-
-
-
Buenos Aires, 아르헨티나, 1058AAJ
- CENydET - Centro Neurobiologico y de Stress Traumatico
-
Buenos Aires, 아르헨티나, C1405BOA
- FunDaMos
-
Buenos Aires, 아르헨티나, 1199
- Hospital Italiano
-
Ciudad Autonoma Buenos Aires, 아르헨티나, C1428AQK
- Hospital Fleni
-
Córdoba, 아르헨티나, X5004AOA
- Instituto Privado Kremer
-
Córdoba, 아르헨티나, 5000
- Fundacion Lennox
-
Córdoba, 아르헨티나, X5006IKK
- Centro Medico Luquez
-
La Plata, 아르헨티나, Thanks
- Clinica Privada de Salud Mental Santa Teresa de Ávila
-
La Plata, 아르헨티나, 1902
- CENPIA
-
Mendoza, 아르헨티나, M5502AWY
- CENAIN
-
San Miguel de Tucumán, 아르헨티나, 4000
- Clinica Mayo de UMCB
-
-
-
-
-
Derby, 영국, DE22 3LZ
- Kingsway Hospital
-
Greater Manchester, 영국, M15 6SX
- Synexus
-
Harrogate, 영국, HG1 2PW
- Garden Valleys Resource Centre
-
London, 영국, SE5 8EF
- Kings College Hospital NHS Trust
-
Redruth, 영국, TR15 2SP
- Cornwall Partnership Foundation Trust
-
-
-
-
-
Hlevakha, 우크라이나, 8631
- MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
-
Kharkiv, 우크라이나, 61068
- Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
-
Kyiv, 우크라이나, 04080
- Kyiv Territorial Medical Incorporation 'Psychiatry'
-
Kyiv, 우크라이나, 1030
- Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
-
Kyiv, 우크라이나, 1034
- Medical Center Health and Happy
-
Nove, 우크라이나, 25491
- Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
-
Ternopil, 우크라이나, 46020
- Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
-
Zaporizhzhya, 우크라이나, 69600
- Zaporizhzhia Regional Clinical Hospital
-
-
-
-
-
Brno, 체코, 60200
- Psychiatricka ambulance Saint Anne s.r.o.
-
Hradec Králové, 체코, 500 09
- NeuropsychiatrieHK, s.r.o.
-
Pilsen, 체코, 301 00
- A Shine S R O
-
Prague, 체코, 100 00
- Clintrial s r o
-
Prague, 체코, 160 00
- NeuropsychiatrieHK, s.r.o.
-
Prague, 체코, 10000
- AD71 s.r.o.
-
Prague, 체코, 186 00
- Institut Neuropsychiatricke pece
-
-
-
-
Nova Scotia
-
Sydney, Nova Scotia, 캐나다, B1P 1E1
- A.K. Munshi Medical Inc.
-
-
Ontario
-
Toronto, Ontario, 캐나다, M3J 2C5
- Canadian Phase Onward
-
-
Quebec
-
Montreal, Quebec, 캐나다, H1M 1B1
- Clinique Force Medic (GCP Trials)
-
-
-
-
-
Bełchatów, 폴란드, 97-400
- Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
-
Bialystok, 폴란드, 15-464
- Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
-
Bydgoszcz, 폴란드, 85-080
- Przychodnia Srodmiescie SP. z o.o.
-
Gdansk, 폴란드, 80 546
- Centrum Badan Klinicznych PI House sp z o o
-
Lodz, 폴란드, 90-009
- Specjalistyczna Indywidualna Praktyka Lekarska
-
Lodz, 폴란드, 90-368
- CCBR - Lodz - PL
-
Lublin, 폴란드, 20-582
- Specjalistyczna Praktyka Lekarska Marek Domanski
-
Poznan, 폴란드, 60-702
- Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
-
Warsaw, 폴란드, 01 737
- Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
-
Warsaw, 폴란드, 02 957
- Instytut Psychiatrii I Neurologii
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
- Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
- Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
- Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
- Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
- Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
- Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
- Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
- Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Seltorexant
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182. |
Participants will receive seltorexant over-encapsulated tablet orally. Participants will receive placebo over-encapsulated tablet matching to seltorexant orally. |
|
활성 비교기: Quetiapine Extended-Release (XR)
Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability. |
Participants will receive quetiapine XR capsule orally. Participants will receive placebo capsule matching to quetiapine XR orally. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
기간: Week 26
|
Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline to Week 26 in Weight
기간: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in weight was reported. |
Baseline (Day 1) and Week 26
|
|
Time to Potentially Treatment Related Discontinuation of Study Drug
기간: From first dose of study drug (Day 1) up to Week 30
|
Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used. |
From first dose of study drug (Day 1) up to Week 30
|
|
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
기간: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in MADRS-6 Total Score
기간: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
기간: Baseline (Day 1) and Week 26
|
The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
기간: Baseline (Day 1) and Week 26
|
Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement. |
Baseline (Day 1) and Week 26
|
|
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
기간: Week 26
|
Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
기간: Week 26
|
Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. |
Week 26
|
|
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
기간: Week 26
|
Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported. |
Week 26
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR108810
- 42847922MDD3005 (기타 식별자: Janssen Research & Development, LLC)
- 2020-000341-14 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .